Genes Dis. 2023 Sep 21;11(5):101120. doi: 10.1016/j.gendis.2023.101120. eCollection 2024 Sep.
NO ABSTRACT
PMID:38831978 | PMC:PMC11145194 | DOI:10.1016/j.gendis.2023.101120
Recent Content
- Canada agency backs coverage of new ovarian cancer drug
- (no title)
- Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
- Therapy wins rare pediatric disease designation for hard-to-treat glioma
- November shines a spotlight on pancreatic cancer awareness
- Cero seeking more safety, dosing data on T-cell therapy for AML
- (no title)
- Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
- Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
- Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma